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Women with polycystic ovary syndrome (PCOS) are more likely to be obese and
have difficulty in losing weight. They demonstrate an obesity-independent
deficit in adaptive energy expenditure. We used a clinically realistic preclinical
model to investigate the molecular basis for the reduced postprandial thermo-
genesis (PPT) and develop a therapeutic strategy to normalize this deficit.
Sheep exposed to increased androgens before birth develop the clinical fea-
tures of PCOS. In adulthood they develop obesity and demonstrate an
obesity-independent reduction in PPT. This is associated with reduced adipose
tissue uncoupling protein expression and adipose tissue noradrenaline concen-
trations. These sheep are insulin resistant with reduced insulin signaling in the
brain. Increasing brain insulin concentrations using intranasal insulin administra-
tion increased PPT in PCOS sheep without any effects on blood glucose concen-
trations. Intranasal insulin administration with food is a potential novel strategy
to improve adaptive energy expenditure and normalize the responses to weight
loss strategies in women with PCOS.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is common, affecting 7%–8% of women of reproductive age, and its inci-
dence is increasing (Fauser et al., 2012). Metabolic dysfunction in PCOS causes lifelong disease and nega-
tively affects the health and well-being of women, their economic productivity, and health service resources
(Jason, 2011). Up to 80% of women with PCOS are overweight or obese (body mass index [BMI] >25 kg/m2),
and in Australia and the United States the prevalence of obesity (BMI >30 kg/m2) in women with PCOS is as
high as 61%–76% (Fauser et al., 2012). Women with PCOS rate obesity as a major concern (Sill et al., 2001),
and increased BMI in PCOS is associated with markedly reduced quality-of-life scores (Ching et al., 2007). In
addition, women with PCOS are more likely to develop glucose intolerance and diabetes (Palomba et al.,
2009). By 30 years of age, 5%–10% of women with PCOS already have type 2 diabetes, 30%–40% have
impaired glucose tolerance, and up to 40% will develop gestational diabetes during pregnancy (Legro
et al., 2005). As the metabolic consequences of PCOS are markedly exacerbated by obesity, and women
with PCOS aremore likely to be obese, understanding and targeting obesity in PCOS is critically important.
The European Society of Human Reproduction and Embryology (ESHRE)/American Society for Reproduc-
tive Medicine (ASRM) consensus on health aspects of PCOS highlighted that ‘‘Mechanistic studies are
necessary to understand the evolution of obesity and PCOS’’ (Fauser et al., 2012).
Obesity can be due to increased energy intake, reduced energy expenditure (EE), or their combinations.
Approximately 65% of energy is expended in maintaining physiological function and 20%–25% by physical
activity. Thus, increasing physical activity, without an equivalent increase in energy intake, promotes weight
loss. The remaining EE is linked to adaptive thermogenesis. Between 10% and 15% of energy is expended
after eating in response to dietary intake (Tseng et al., 2010). We have assessed EE after feeding in women
with PCOS using continuous indirect calorimetry. These women show an obesity-independent reduction in
peak postprandial thermogenesis (PPT) to 73.2% G 6.9% of weight-matched controls (Robinson et al.,
1992). This suggests that the high prevalence of obesity in women with PCOS may be related to altered
adaptive thermogenesis that is not a consequence of obesity.iScience 23, 101164, June 26, 2020 ª 2020 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Postprandial Thermogenesis and Weight
(A) Weight of C-sheep (n = 11) and PCOS-sheep (n = 4) from birth to 30 months. Adulthood is indicated by the dotted line.
(B) Two subsets of C-sheep showing the obese (O) (n = 4) and normal (N) (n = 4) controls and the PCOS-sheep (n = 4).
(C) The basal body temperature in the normal (N) C-sheep, the obese (O) C-sheep, and the PCOS-sheep.
(D) The temperature increase after feeding as a function of time in PCOS-sheep and C-sheep at 30 months of age.
(E) The maximal minus the minimum temperature after feeding in the (N) C-sheep, the (O) C-sheep, and the PCOS-sheep.
(F) The time to maximum temperature in the (N) C-sheep, the (O) C-sheep, and the PCOS-sheep. Data are represented as




ArticleAdult Scottish Greyface ewes weigh up to 85 kg and are ideally suited to longitudinal preclinical studies
involving serial sampling and multiple tissue analysis. The female offspring of women (Barnes et al.,
1994), non-human primates (Abbott et al., 2013), and sheep (Padmanabhan and Veiga-Lopez, 2013)
exposed to increased androgens during mid-pregnancy manifest ovarian, hormonal, and metabolic phe-
notypes reminiscent of PCOS. We have used the gestational androgenization ovine model to provide in-
sights into the molecular pathophysiology of PCOS and its antecedents (Ramaswamy et al., 2016) and also
to examine therapeutic paradigms (Connolly et al., 2014). After maternal gestational androgen exposure,
female offspring develop polycystic ovaries, thecal hyperandrogenism, progressive insulin resistance (IR),
and fatty liver in adulthood (Ramaswamy et al., 2016; Connolly et al., 2014; Hogg et al., 2011, 2012; Rae
et al., 2013). Using the protocol described in this article 100% control sheep regularly ovulated in the sec-
ond breeding season, at around 2 years of age, whereas only 25% PCOS sheep showed any evidence of
ovulation.
We hypothesized that the ovine model of PCOS could be used to dissect the pathophysiology of impaired
PPT in women and inform and test novel treatment paradigms. Herein we show that sheep prenatally pro-
grammed to have PCOS have increased weight in adulthood and this is associated with an obesity-inde-
pendent deficit in PPT, of the same magnitude as that seen in women with PCOS, which is correlated
with IR. Using this clinically realistic model we investigated EE in adipose tissue and its sympathetic stim-
ulation as well as insulin signaling in the brain. We then investigated whether increasing insulin signaling in
the brain using an intranasal insulin (INI) aerosol spray could safely normalize adaptive EE after feeding.RESULTS
Increased Body Weight in the Ovine PCOS Model
Female offspring of sheep exposed to increased androgens during pregnancy (PCOS-sheep) show no dif-




Article(Figure 1A). However, in adulthood, at 2 years of age, they have increased body weight when compared
with control animals (C-sheep) (PCOS-sheep: 72.0G 0.91 kg; C-sheep: 64.9G 1.98 kg; p = 0.006). This in-
crease in body weight is maintained until the end of the experiment at 30 months of age (PCOS-sheep:
85.75G 0.75 kg; C-sheep 79.73G 1.58 kg; p = 0.004; Figure 1A). PCOS-sheep are prenatally programmed
to develop increased body weight in adult life.Deficit in Postprandial Thermogenesis
We selected the four heaviest C-sheep (85.5G 1.25 kg), whose weight was not different from that of the PCOS-
sheep (p = 0.98), and the four lightest C-sheep (74.75 G 0.75 kg), which were significantly lighter than the
heaviest C-sheep (p < 0.0001) and the PCOS-sheep (Figure 1B, p < 0.0001), for further detailed study. PPT
was examined by direct temperature sensing from the interscapular adipose tissue using datalogger-implanted
thermometers. There were no differences in basal body temperature between the C-sheep and PCOS-sheep
(Figure 1C). After feeding, all sheep had robust and predictable PPT manifest by a temperature increase.
PCOS-sheep had a significant reduction in PPT (p < 0.05; Figure 1D) when compared with C-sheep. This was
the same regardless of the weight of the C-sheep. The reduction of EE after feeding in the PCOS-sheep was
74.7%G 8.2% of that of controls and 72.1%G 7.9% of weight-matched controls (Figure 1E). Along with reduc-
tion in the temperature increase, the PCOS-sheep took longer to reach this maximal temperature (p < 0.05; Fig-
ure 1F). PCOS-sheep are prenatally programmed to have reduced PPT.Association with Insulin Resistance
At 2 years of age the PCOS-sheep were hyperinsulinemic. They showed no differences in glucose dynamics
during an intravenous glucose tolerance test (GTT) (Figure 2A), but they had significantly increased area
under the curve insulin concentrations (p < 0.05; Figures 2B and S1). At that stage the fasting insulin con-
centrations were not different from controls (p = 0.298; Figure 2C). However, at 30 months of age fasting
insulin was increased in PCOS-sheep (p < 0.05; Figures 2D and S1). They showed evidence of IR in the fast-
ing state with reduced basal glucose to insulin ratio (p < 0.05; Figures 2E and S1). Fasting insulin concen-
trations showed a negative correlation with the temperature difference during PPT (R = 0.56, p < 0.05;
Figure 2F) and a positive correlation with the time to maximal temperature (R = 0.56, p < 0.05; Figure 2G).
The reduction in PPT correlates with the degree of IR.Molecular Analysis of Muscle and Fat Depots
We examined the expression of genes linked to thermogenesis and calcium cycling in skeletal muscle.
There were no differences in their transcript abundance in the muscle of PCOS-sheep when compared
with C-sheep (Figure 3A). We next examined the expression of the transcripts of thermogenic uncoupling
proteins in four different adipose tissue sites (Figure 3B). UCP1 was reduced in both subcutaneous (neck
and groin; p < 0.05) and visceral (p < 0.01) adipose depots (Figures 3C and S1). In addition, UCP2 (p <
0.05) and UCP3 (p < 0.05) were reduced in the subcutaneous back fat (Figures 3D, 3E, and S1). After check-
ing antibody specificity for sheep tissue (Figure S1), immunohistochemistry was carried out for UCP1 and
UCP3 in the sites with the biggest differential expression. UCP1 protein could be consistently identified
in subcutaneous (groin) fat in C-sheep (Figure 3F), but it was largely absent from PCOS-sheep (Figure 3G).
Its expression correlated with the temperature increase after eating (R = 0.66, p < 0.05; Figure 3H). Similarly,
UCP3 protein was clearly seen in the subcutaneous (back) adipose tissue in C-sheep (Figure 3I) and less so
in the PCOS-sheep (Figure 3J). Its expression correlated with the thermogenesis response (R = 0.72, p <
0.01; Figure 3K). The reduction in PPT is associated with reduced UCP expression in adipose tissue.Reduction in Adipose Tissue Sympathetic Signaling
As adipose tissue UCP expression is primarily regulated by sympathetic innervation we measured the tran-
script abundance for b-adrenergic receptors in the fat depots (Figure 4A). As there was no difference in re-
ceptor expression we measured the content of noradrenaline (NA) in the fat depots. There was a reduction
in NA concentrations in subcutaneous (neck and groin) and visceral adipose tissue (Figure 4B). In addition,
the mean NA concentrations in all fat depots were significantly lower in PCOS-sheep than control sheep
(p < 0.05; Figure 4C). The adipose tissue NA concentration correlated with PPT (R = 0.58, p < 0.05; Fig-
ure 4D) and was inversely correlated with body weight (R = 0.59; p < 0.05; Figure 4E). There is a reduction
in the sympathetic drive in the fat depots of PCOS-sheep.iScience 23, 101164, June 26, 2020 3
Figure 2. Insulin Resistance
(A and B) (A) Plasma glucose and (B) insulin in the 45 min after an IV GTT in C-sheep and PCOS-sheep at 24 months of age.
(C and D) (C) Fasting insulin concentrations at 24 months and (D) 30 months in C-sheep and PCOS-sheep.
(E) Fasting glucose to insulin ratio in C-sheep and PCOS-sheep at 30 months of age.
(F) Correlation between postprandial temperature difference and fasting insulin concentrations (p < 0.05).
(G) Correlation between fasting insulin concentrations and time to maximal postprandial temperature (p < 0.05). Data are
represented as mean G SEM. *p < 0.05.
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Figure 3. Expression of UCPs
(A) Relative mean gene expression G SEM measured by RT-PCR in skeletal muscle for uncoupling proteins and genes
involved in futile calcium cycling.
(B–J) (B) Diagram highlighting the adipose tissue depots studied: the neck (N) fat, inter-scapular back (B) fat, visceral (V)
fat, and subcutaneous groin (G) fat. Relative expression of (C) UCP1, (D) UCP2, and (E) UCP3 in the four adipose tissue
depots. Immunohistochemistry for UCP1 (brown) in G fat from (F) C-sheep and (G) PCOS-sheep. (H) Correlation between
UCP1 expression in G fat and postprandial temperature increase (p < 0.05). Immunohistochemistry for UCP3 (brown) in B
fat from (I) C-sheep and (J) PCOS-sheep.
(K) Correlation between UCP3 expression in B fat and postprandial temperature increase (p < 0.05). All immunochemistry





ArticleCentral Insulin Signaling in the Ovine PCOS Model
As brain insulin action can regulate sympathetic drive to adipose tissue primarily through hypothalamic ac-
tion, and IR correlated to reduced PPT, we assessed central insulin signaling in C-sheep and PCOS-sheep.
Insulin signaling, assessed by pERK immunohistochemistry, was evident in cells within the hypothalamus
(Figure 5A), whereas quantification of the degree of signaling using western blotting in this tissue that
has marked functional regional differences was challenging. We therefore examined a consistent region
of the frontal cortex. There were no differences in the expression of the key elements of the insulin signaling
pathway (Figures 5B–5D). However, there was a difference in insulin signaling (Figure 5E). The reduction in
the expression of pAKT almost reached significance (p = 0.057; Figure 5F) in PCOS-sheep, whereas cere-
bral pERK was consistently reduced in PCOS-sheep (p < 0.05; Figure 5G). There is evidence for decreased
insulin signaling in the brain of PCOS-sheep.
The Effect of Intranasal Insulin of Postprandial Thermogenesis
To test whether raising intracerebral insulin could improve PPT in PCOS-sheep, we developed another
cohort of PCOS sheep. The insulin response to an intravenous GTT increased in adolescence at 11 months
of age and further increased in adulthood (Figure 6A). At 20 months of age the insulin concentrations (Fig-
ure 6B) and basal glucose:insulin ratio (Figure 6C) were outwith age-matched historical controls, suggest-
ing IR. Administration of 10 IU insulin intranasally showed no change in blood glucose concentration over
the next hour in one test animal (Figure 6D). In the cohort of PCOS-sheep INI showed no effects on blood
glucose over 10 min in the absence (Figure 6E) or presence of food (Figure 6F). Interestingly there was no
increase in serum insulin after INI in the absence of food (Figure 6G), but when given with food there was an
increase in serum insulin concentrations (p < 0.05; Figure 6H), suggesting an endogenous response to
food. INI significantly increased the PPT response in PCOS-sheep (p < 0.05; Figure 6I). In addition, there
was a small effect on PPT with insulin (p < 0.05; Figure 6I) in the absence of feeding. Therapeutically
increasing cerebral insulin increases PPT in PCOS-sheep.
DISCUSSION
Manipulation of the hormonal environment in utero by increasing maternal androgen concentrations has
important effects on the female offspring. In adulthood they have increased body weight when compared
with control female offspring. As these sheep were genetically outbred, randomly allocated to treatment,
and share the same paternal genetic component, this increased weight is environmental rather than ge-
netic. The postnatal sheep share the same postnatal environment suggesting that they are prenatally pro-
grammed to become overweight in adult life. This is another example of the far-reaching consequences of
endocrine disruption in utero and the lifelong importance of the prenatal environment (Gore et al., 2015).
There are numerous examples of developmental programming of adult metabolic dysfunction and a very
clear link to fetal undernutrition, lower birthweight, catch-up growth, and ultimate obesity (Ravelli et al.,
1976; Hales and Barker, 1992; Isganaitis, 2019). In this case the birthweight was normal as was weight
gain until adolescence as increased weight was manifest in early adulthood. However, in similar ovine
models of PCOS using testosterone administration from D30 gestation there is some evidence of growth
restriction and masculinization of external genitalia at birth (Padmanabhan and Veiga-Lopez, 2013). We
have shown that growth restriction is not seen when testosterone is given after the male programming win-
dow at D60 gestation. The PCOS-sheep are prenatally programmed to become obese in later life.
Obesity in early adulthood is common in women with PCOS (Fauser et al., 2012; Ollila et al., 2016) and
like the PCOS-sheep women with PCOS do not show consistent evidence of prenatal undernutrition6 iScience 23, 101164, June 26, 2020
Figure 4. Sympathetic Activity
(A) Relative mean gene expression G SEM for b-adrenergic receptors, measured by RT-PCR, in the neck (N), inter-
scapular back (B), visceral (V), and subcutaneous groin (G) adipose tissue depots in C-sheep and PCOS-sheep.
(B) NA concentrations in the four adipose tissue depots in C-sheep and PCOS-sheep.
(C–E) (C) Four-site average NA concentrations in adipose tissue in C-sheep and PCOS-sheep. Correlation of adipose
tissue NA concentrations and (D) postprandial temperature increase (p < 0.05) and (E) body weight at 30 months of age




Article(Sadrzadeh et al., 2017). This is consistent with a prenatal programming contribution to obesity in women
with PCOS.
Obesity is an outcome of a mismatch between energy intake and expenditure. There are inconsistent data
regarding energy intake in women with PCOS, but the majority of studies found no differences in daily food
and nutrient consumption in women with PCOS when compared with controls (Wright et al., 2004; Altieri
et al., 2013). Wright et al. reported that womenwith PCOSwith a normal BMI consumed a significantly lower
number of calories (R250 kcal/day) than BMI-matched controls, hypothesizing that this might be necessary
to prevent weight gain in these women (Wright et al., 2004). Studies evaluating physical activity levels in
women with and without PCOS are more consistent, reporting no difference in overall levels of physical ac-
tivity (A´lvarez-Blasco et al., 2011). A limited number of studies have looked at basal metabolic rate in
women with PCOS, and most studies show no difference in PCOS when compared with weight-matched
controls (Larsson et al., 2016). Collectively, these observations suggest that the defect is in adaptive EE.
We have previously assessed EE after feeding in women with PCOS using continuous indirect calorimetry
(Robinson et al., 1992). These women show a reduction in peak PPT to 73.2% G 6.9% of weight-matched
controls (Robinson et al., 1992). Here we provide evidence from female sheep that suggests that this defect
in EE can be prenatally programmed, by androgen in this case. The PCOS-sheep had an identical reduction
in peak PPT (72.1%G 7.9% of weigh-matched controls). This suggests that the high prevalence of obesity in
women with PCOSmay be related to altered adaptive thermogenesis that is not a consequence of obesity.
There are a lot of discrepancies regarding the potential role of decreased PPT in obesity, mainly due to
differences in patient selection and methodologies (Granata and Brandon, 2002). However, in women
with PCOS, normalizing PPT, in the absence of increased energy intake, would be expected to promote
weight loss to enhance health and well-being.iScience 23, 101164, June 26, 2020 7
Figure 5. Central Insulin Signaling
(A–D) (A) Immunohistochemistry for pERK (brown) in the hypothalamus of C-sheep. Inset is negative control serial section. Relative mean gene expressionG
SEM for (B) INSR (IR), (C) IRS1, and (D) IRS2 in the frontal cortex of C-sheep and PCOS sheep.
(E) Representative western blot of AKT, phospho-AKT (pAKT), ERK, and phospho-ERK (pERK) in the frontal cortex of C-sheep and PCOS-sheep with a-tubulin
as a loading control. The size representation in kDa, determined by a molecular weight marker ladder, is shown to the left. Sheep were sacrificed 15 min after
an intravenous glucose bolus.
(F) Quantification of pAKT to ATK ratio in the frontal cortex in C-sheep and PCOS-sheep.




ArticleTo normalize PPT in women with PCOS it is necessary to interrogate the molecular mechanisms of reduced
PPT. As rodents, with a small size and correspondingly high body surface area, have a large capacity for
thermogenesis, as a consequence of brown adipose tissue (BAT) (Reitman, 2018), they are not ideal to study
PPT in adult humans who do not have the same proportion of BAT. BAT is present in newborn lambs,
whereas it cannot be routinely detected in adult sheep. In sheep like women there may be features of
BAT, such as UCP expression, in ‘‘white’’ adipose tissue (WAT), but any changes in function are changes
in the function of WAT rather than classical BAT. In addition, there are challenges recapitulating the entire
phenotype of women with PCOS using rodent models (McNeilly and Duncan, 2013). The ovine model of
PCOS, as a consequence of prenatal androgenization (Padmanabhan and Veiga-Lopez, 2013, Connolly
et al., 2014; Hogg et al., 2012; Birch et al., 2003), provides a clinically realistic model of PCOS in a large an-
imal with hormonal, ovarian, and metabolic phenotypes equivalent to women with PCOS. Importantly this
model has the same obesity-independent deficit in PPT as seen in women with PCOS.
Thermogenesis is a consequence of increased heat generation by metabolic tissues independent of blood
flow (Clarke et al., 2012). Effector tissues, such as fat, muscle, and liver, shape the thermogenic response by
increasing heat generation. The defect in PPT seen in the PCOS-sheep is associated with a reduction in the
expression of uncoupling proteins in adipose tissue. UCP1 is the master effector of thermogenesis in
adipose tissue. Mice lacking UCP1 become obese when consuming normal diets (Feldmann et al., 2009).
Rodents fed on a highly palatable diet voluntarily overfeed but have an ability to dissipate extra energy8 iScience 23, 101164, June 26, 2020
Figure 6. Intranasal Insulin Administration
(A) Assessment of plasma insulin concentrations before and up to 45 min after intravenous (i.v.) GTT in the second cohort
of PCOS-sheep (n = 12) at 9, 11, 17, and 20 months of age.
(B) Plasma insulin concentrations after i.v. GTT at 20 months of age (black) showing the mean G SEM of historical age-
matched C-sheep (gray).
(C) The fasting glucose to insulin ratio in these PCOS-sheep with the meanG SEM of historical age-matched C-sheep (gray).
(D–H) (D) The effect of 10 IU intranasal administration over 60 min of plasma glucose concentration in a single PCOS-
sheep. The effect of 10 IU insulin 10 min after administration on plasma glucose in PCOS-sheep (n = 12) in the absence (E)
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or presence (F) of feeding. The effect of 10 IU insulin 10 min after administration on plasma insulin in PCOS-sheep
(n = 12) in the absence (G) or presence (H) of feeding.
(I) Temperature increase in PCOS-sheep at 20 months of age as a function of time from feeding (black), after feeding with
10 IU intranasal insulin (gray) and after 10 IU intranasal insulin without feeding (gray dashed line). Data are represented as




Articleas heat with a significant increase in UCP1, both at mRNA and protein levels, in BAT (Falcou et al., 1985).
Genetically fat sheep have reduced PPT when compared with lean animals, and this is likely to be a conse-
quence of decreased UCP1 expression in retroperitoneal adipose tissue (Henry et al., 2015). Indeed, in hu-
man studies, UCP1 polymorphisms are related to decreased PPT (Nagai et al., 2003). The subpopulation of
control sheep that were obese did not show a UCP expression like the PCOS-sheep highlighting further the
prenatally programmed alterations in adult adipose tissue function.
Although the role of UCP1 in adaptive thermogenesis is well established, the precise function of UCP2 and
UCP3 in cells remains unknown. As UCP2 and UCP3 have 60% sequence identity with UCP1 and 70%
similarity with each other it is likely that they have similar biochemical functions (Esteves and Brand, 2005). Ro-
dents overexpressing UCP2/UCP3 have decreased adiposity and are protected from diet-induced obesity
(Horvath et al., 2003) although, unlike UCP1, UCP2/UCP3may have a role in free fatty acidmetabolism (Bezaire
et al., 2005). A study in a dehydroepiandrosterone-induced rat model of PCOS demonstrated that PCOS-like
rats have significantly reduced BAT activity with decreased UCP1 and lower thermogenic capacity (Yuan et al.,
2016). However, UCP transcript abundance might not parallel protein expression and activity and there may
be other explanations for the reduction in PPT in PCOS-sheep. Overall, though, it seems that reduced ther-
mogenesis in the PCOS-sheep is a consequence of adipose tissue dysfunction.
There are several potential regulatory mechanisms driving the thermogenic response, but it is clear that
the sympathetic nervous system has a major role in the overall regulation of PPT (Wijers et al., 2009).
BAT thermogenesis is controlled by the sympathetic nervous system, where localized release and action
of NA activates UCP1 (Tseng et al., 2010). Depletion of the adrenoceptors ADBR1, ADBR2, and ADBR3
in thermogenic adipose tissue results in an obese phenotype and decreased UCP1 expression (Lowell
et al., 1993). Feeding is associated with sympathetic activation and increased sympathetic nerve firing,
and this effect is regional as there is no increased NA spill to the heart or associated cardiovascular effects
(Cox et al., 1995). This is correlated closely with heat production (Schwartz et al., 1987).
An adrenaline infusion increases PPT and peripheral oxygen consumption, which is reduced by b-blockade
(Astrup et al., 1989). Women with diminished PPT have a normal thermic response to adrenaline suggesting
that a reduction in sympathetic activity rather than sensitivity to adrenaline is involved in impaired PPT (For-
bes et al., 2009). Starvation reduces the central sympathetic drive for thermogenesis (Wijers et al., 2009),
and genetically obese rodents have lower sympathetic activity in BAT (Knehans and Romsos, 1982). To
our knowledge there have been no studies looking at NA concentrations in the adipose tissue of women
with PCOS but there is evidence for decreased adrenergic responses in adipose tissue from women with
PCOS (Faulds et al., 2003). Overall this suggests that reduced sympathetic nervous system signaling in ad-
ipose tissue may be responsible for the reduced PPT.
IR and compensatory hyperinsulinemia are key factors contributing to the pathophysiology of PCOS (Dia-
manti-Kandarakis and Dunaif, 2012). It is estimated that as many as 50%–70% women with PCOS are insulin
resistant, independent of BMI (DeUgarte et al., 2005; Stepto et al., 2013). On average, insulin sensitivity is
decreased by 35%–40% in patients with PCOS when compared with matched controls (Diamanti-Kandar-
akis and Dunaif, 2012). The reduction in PPT in women with PCOS correlates with IR (Robinson et al., 1992),
and this is also the case in the PCOS-sheep. This link between insulin sensitivity and reduced PPT has also
been shown by others, although themechanisms are still not fully understood (Ravussin et al., 1985; Camas-
tra et al., 1999). However, peripheral IR has been shown to be associated with reduced insulin sensitivity in
the central nervous system (CNS) (Benedict et al., 2011).
Insulin enters the CNS through the blood-brain barrier, and although the details of this process are un-
known, it is thought to be through a receptor-mediated mechanism (Plum et al., 2005). Insulin receptors
are widespread in the brain with high populations found in the cerebellum, cerebral cortex, hippocampus,




Articleof insulin signaling in response to food (Guthoff et al., 2010) and weight regulation with increasing insulin
causing weight loss and inhibition of signaling causing weight gain (Plum et al., 2005). Reduced insulin
signaling in the brain, in the presence of increased plasma insulin, has been identified in obese states high-
lighting a role of central insulin signaling in the pathophysiology of obesity (Kern et al., 2006). One thing
that we were not able to investigate was transport of insulin into the CNS. It remains plausible that part
of the reduced central insulin signaling relates to insulin transport as well as insulin action.
There is a sympathoexcitatory response to hyperinsulinemic clamp (Ward et al., 2011). Direct injections of
insulin into the preoptic area of the mouse hypothalamus activate BAT thermogenesis and stimulate in-
crease in core body temperature in a dose-dependent manner (Sanchez-Alavez et al., 2010), through neural
mechanisms. In addition, the thermogenic activity in mouse BAT declines with insulin deficiency (Shibata
et al., 1987). Direct administration of leptin into the brain also stimulates peripheral thermogenesis in large
animal models through increased sympathetic nerve activity (Henry et al., 2008). We showed that insulin
signaling in the brain of PCOS-sheep is reduced in the presence of the insulin receptor pathway. This is
consistent with central insulin signaling having a key role in the regulation of PPT.
Nasal administration of proteins allows them to travel directly to the brain along the olfactory nerve and
perivascular channels and is a novel strategy to facilitate central delivery and action (Meredith et al.,
2015). In humans INI administration increases cerebrospinal fluid insulin concentrations within 60 min
without adversely affecting blood insulin or glucose concentrations (Craft et al., 2012). In healthy men,
INI did not change resting metabolism but increased PPT by 17% (Benedict et al., 2011). In Alzheimer dis-
ease there is reduced central insulin activity, and INI improved memory and functional ability without pe-
ripheral insulin effects (Craft et al., 2012). In pilot studies INI over 8 weeks reduced body fat in normal men
(Hallschmid et al., 2004). This reduction was not seen in normal women (Hallschmid et al., 2004). However,
this has not been examined in women with PCOS who, like men, are more insulin resistant, are exposed to
increased androgens during development and adult life, and have more android fat distribution.
INI administration in humans is safe and has been assessed in Alzheimer disease (Craft et al., 2012), other
neurological conditions, and diabetes mellitus (Fourlanos et al., 2011). There were no serious adverse
events reported due to INI administration. In some articles, there were reports of nose soreness, nose
bleeding, mild rhinitis, nasal dripping, and sneezing due to nasal administration. The doses of INI ranged
from 20 to 160 IU in each single administration, with the highest dose in a single day totaling 420 IU (Ott
et al., 2015). In our studies, to ensure safety, we opted to test a small dose of insulin and showed an effect
at 10 IU. The administration of INI in sheep, like in humans, is well tolerated and safe.
INI has been used to investigate food intake in humans. Benedict et al. administered INI to normal-weight
subjects before presenting an ad libitum breakfast buffet, to determine a possible difference in food intake
between sexes (Benedict et al., 2011). Intranasal administration reduced the free-choice intake of carbohy-
drates. Food intake was reduced in men but not women, suggesting that men may be more sensitive to the
anorexigenic effects of increased central insulin action. Men who had been administered INI exhibited a
significant decrease in total calorie intake (Jauch-Chara et al., 2012). Food-related neuronal activity moni-
toring showed that INI increased the cerebral processing of food images in lean subjects, but there was no
effect in obese subjects, suggesting a degree of central IR associated with obesity (Guthoff et al., 2011). INI
is a safe therapeutic strategy to raise central nervous system insulin concentrations and action.
We suggest that women with PCOS may be prenatally programmed to have altered adaptive EE,
manifest by a defect in PPT, which predisposes to obesity. INI taken with food will enhance the deficient
central effects of this hormone and normalize the thermogenic response in effector tissues. In addition,
INI alone without feeding also increased thermogenesis. INI may also have the added benefit of reducing
food intake giving dual benefits in weight loss strategies. This suggests the utility of a pilot study investi-
gating INI on PPT in women with PCOS. INI administration with food has the potential to be a convenient,
accessible, and safe therapeutic strategy to normalize PPT and facilitate weight loss in women with PCOS.Limitations of the Study
Although we used a clinically realistic large animal model, which showed the same defect in PPT as women with
PCOS, further research in women is required to determine if the mechanistic and therapeutic elements discov-




Articlethis work. However, working with large animals with a long lead-time to adulthood gives particular experimental
challenges with regard tomolecular tools and replicates. We inferred biological activity in fat by looking at tran-
script abundance, and further research looking at detailed adipose tissue mitochondrial function in vitro would
enhance the findings. In the therapeutic studywe focused on PCOS-sheep, and doubling the size of the study to
include contemporaneous randomized controls would have been a robust strategy, if additional funding was
available. Similarly, additional animals where we were able to examine insulin signaling in the brain after nasal
administration, rather than just systemic glucose administration, would have given valuable information.
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Gene  Forward Sequence  Reverse Sequence  Size (bp)
GAPDH  GGCGTGAACCACGAGAAGTATAA AAGCAGGGATGATGTTCTGG  229 
ACTB  ATCGAGGACAGGATGCAGAA  CCAATCCACACGGAGTACTTG  101 
MDH1  TTATCTCCGATGGCAACTCC  GGGAGACCTTCAACAACTTTCC  100 
RPS26  CAAGGTAGTCAGGAATCGCTCT  TTACATGGGCTTTGGTGGAG  106 
18S  CAACTTTCGATGGTAGTCG  CCTTCCTTGGATGTGGTA  110 
RYR1  GGACCTCATCGGCTACTTTG  GACATTTAGGCGGTCAATGC  151 
ATP2A1  GACAGGGTAGATGGGGACCT  GTCCAAGGAGGAGTCATTGC  171 
ATP2A2  GGTGCTCCTGAAGGTGTCAT  CAGTGGGTTGTCATGAGTGG  168 
UCP1  AGAGCCATCTCCACGGTCCCA  CCAAAGCCCCGTCAAG  92 
UCP2  AAGGCCCACCTAATGACAGA  CCCAGGGCAGAGTTCATGT  128 
UCP3  AGATGAGCTTCGCCTCCAT  TGAAAGCGGATCTTCACCAC  172 
ADRB1  CTTCTTCCTGGCCAACGTG  GGGTTGAAGGCCGAGTTG  105 
ADRB2  CATGCCCAAAACGTCAGTC  TCTTGAGGGCTTTGTGTTCC  100 
ADRB3  GCACCCAATACTGCCAACG  GTTGGTCATGGTCTGGAGTCT  159 
INSR  CACCATCACTCAGGGGAAAC  CAGGAGGTCTCGGAAGTCAG  247 
IRS1  ATCATCAACCCCATCAGACG  GAGTTTGCCACTACCGCTCT  240 
IRS2  CCCGCGCCGGTGGCCCGCATCA  AGCAACACGCCCGAGTCCATC  263 
 
Table 1. PCR primers 
Forward and reverse primer sequences and product sizes for genes analysed in adipose and 
cerebral tissues. 
 
Western blotting 
Tissues (30‐50mg) were homogenised in lysis buffer (150mM NaCl, 10mM Tris pH 7.4, 1mM 
EDTA, 1mM EGTA, 1% TrixonX‐100, 0.5% NP‐40, 0.5mM phenylmethyl sulfonyl fluoride, 
supplemented with 1 Complete mini tablet and 1 PhosSTOP tablet (Roche, West Sussex, UK) 
per 10 ml buffer.) Samples were pre‐cleared by incubating with Protein G agarose beads 
(Cell Signalling Technology) for 1 hour at 4°C. Protein concentration was quantified using a 
Bio‐Rad DC protein assay (Bio‐Rad Laboratories Ltd, UK) kit following manufacturer’s 
instructions. Samples (25µg) were diluted in Laemmli loading buffer (62.5 mM Tris, pH 6.8, 
2% SDS, 1% β‐mercaptoethanol, 10% Glycerol, 0.01% Bromophenol Blue), denatured by 
heating to 95°C for 5 min and loaded on 15 well 12% mini‐ PROTEAN TGX precast gels (Bio‐
Rad Laboratories Ltd, Watford, UK) alongside pre‐stained full‐range molecular weight 
markers (GE Healthcare, Buckinghamshire, UK). Proteins were then transferred onto 
Immobilon‐FL polyvinylidene difluoride (PVDF) membrane (Merck Millipore Ltd, Cork, 
Ireland) using a wet tank transfer system. 
Membranes were dried, rinsed and blocked for 1 hour at room temperature in 
Odyssey Blocking Buffer (PBS; LI‐COR Biotechnology‐UK Ltd, Cambridge) and then probed 
with the primary antibodies raised against phospho‐ERK (Phospho‐p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) Antibody #9101 Cell Signalling Technology) or phospho‐AKT (Phospho‐Akt 
(Ser473) (D9E) XP Rabbit mAb #4060, Cell Signalling Technology) at 1:1000 in blocking 
buffer. Mouse anti‐α ‐Tubulin (Sigma Aldrich, UK) at 1:3000 was used as a control for 
protein loading. For UCP3 western blots the primary antibody (polyclonal goat anti‐human) 
was used at a concentration of 1:200 with the negative control 1:200 of 10% normal goat 
serum. The membrane was incubated in the primary antibody solution overnight at 4°C with 
gentle agitation. After washing the membrane was incubated in secondary antibody 
solution (1:10000 IRDye 800CW Donkey‐anti‐Rabbit, IgG + 1:10,000 IRDye 680RD Donkey 
anti‐Mouse IgG; LI‐COR Biotechnology, Cambridge, UK) or Donkey anti‐Goat IRDye 800 at 
1:10000 dilution, in blocking buffer, washed and visualised on the Odyssey Fc Imaging 
System (LI‐COR Biotechnology). After visualisation, antibodies were stripped from the 
membranes using stripping buffer (25mM glycine pH 2, 1% SDS) and re‐labelled with 
primary antibody for either total‐ERK (p44/42 MAPK (Erk1/2) Antibody #9102; Cell Signalling 
Technology) or total‐AKT (Akt Antibody #9272, Cell Signalling Technology). Protein was 
quantified using Image Studio Lite v5.2 (LI‐COR Biotechnology) and the ratio of 
phosphorylated protein: total protein calculated. 
Noradrenaline ELISA 
A representative sample of adipose tissue was cut on dry ice and homogenised in 
homogenisation buffer (HCl 0.01N; EDTA 1mM; sodium metabisulfite (Na2S2O5) 4mM) using 
TissueLyser (Qiagen Ltd.) at 25Hz for 4 min. The protein concentration of the homogenate 
supernatant was quantified by the Bradford assay. Noradrenaline concentrations were 
measured using Noradrenaline Research ELISA (ImmunSmol, BA E‐5200, Pessac, France) as 
per the manufacturer’s instructions. All samples were assayed in duplicate and results were 
corrected by the total protein content in the sample. The assay sensitivity was 0.1ng/ml and 
intra‐ and inter‐assay CVs were <8.4% and <6.9% respectively. 
Intranasal insulin 
For the second cohort of PCOS‐sheep small implantable temperature data loggers (DST 
Mini‐T; AnimaLab, Poznan, Poland) were implanted into the interscapular adipose tissue 
under local anaesthetic. Animals recovered from the surgery for 10 days prior to 
assessment. After the use of a feeding schedule to entrain a morning feeding response the 
ewes were studied on 9 separate occasions in individual pens from 09.00h until 16.00h. 
Temperature was recorded every minute before during and after timed feeding. Three 
interventions were conducted in triplicate. The data from the three replications were 
combined and the mean data used for analysis. The three interventions assessed were: 
eating alone, eating with intranasal insulin (10IU; Hypurin bovine insulin; Intervet UK Ltd.; 
diluted in saline to 0.5ml) administered through LMA MAD Nasal Intranasal Mucosal 
Atomisation Device (Teleflex, Athlone, Ireland) to the left nostril, or intranasal insulin alone 
administered as above. In pilot experiments blood samples were measured every 5 minutes 
for glucose assessment. In the first run of each experiment blood was taken before and 10 
minutes after nasal insulin administration for glucose and insulin assessment. 
Statistics 
Statistical analysis was performed with GraphPad Prism version 6.0 (GraphPad Software 
Inc., San Diego, CA). For comparing means of two groups with equal variances an unpaired, 
two‐tailed, Student’s t‐test was used. Log transformation was used to allow for parametric 
analysis when necessary. For more than two comparisons ANOVA was used with Bonferroni 
pairwise comparisons. Results are presented as Mean ±SEM and a P‐value of <0.05 was 
considered statistically significant. Area under the curve (AUC) was calculated using the 
trapezoidal method. Correlation was assessed by calculation of the Pearson R co‐efficient 
and a line of best fit was incorporated for statistically significant correlations. The maximal 
postprandial temperature response was calculated as the average time from feeding to the 
first reading of the peak temperature per sheep. 
Study approval 
These studies were conducted after institutional ethics review and UK Home Office approval 
(PPL60/4401). All experiments complied with the relevant regulatory standards. 
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